

KOL2025
KOL2025
KOL2025
KOL2025

The KOL Haematology Research, Strategy and Support Forum

9th May 2025

Disclaimer

The following disclaimer applies to this presentation

For the purposes of this disclaimer, "Presentation" means this document, its contents or any part of it, any oral presentation, any question or answer session and any written or oral material discussed or distributed during the Presentation meeting. The purpose of this Presentation is to provide an overview of the interim financial results of (the "Company") and its subsidiary undertakings (the "Group"). The information in this Presentation is not intended to form the basis of any contract.

This Presentation does not constitute an offer or invitation for the sale, issuance or purchase of securities or any businesses or assets described in it, nor does it give or purport to give legal, tax or financial advice. Nothing herein shall be taken as constituting the giving of investment advice or an inducement to enter into investment activity in any jurisdiction and this Presentation is not intended to provide, and must not be taken as, the basis of any decision and should not be considered as an invitation, inducement, solicitation or recommendation to purchase, underwrite, subscribe for or otherwise acquire any securities of the Group. The recipient must make its own independent assessment and such investigations as it deems necessary. Save as set out below, the Presentation has been prepared on the basis of information held by the Group and also from publicly available information. This information, which does not purport to be comprehensive, has not been independently verified by or on behalf of the Group. The Presentation does not constitute an audit or due diligence review and should not be construed as such.

The Company nor any of its subsidiary undertakings or any of such persons' respective directors, officers, employees, affiliates, advisers or agents (their "Associates") accepts any responsibility, obligation or liability whatsoever for, or makes any representation or warranty, express or implied, as to, and no reliance should be placed on, the fairness, truth, fullness, accuracy, completeness or correctness of, the information in this Presentation or whether any information has been omitted from the Presentation or as to any other information relating to the Company or the Group, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of this Presentation, its contents or otherwise arising in connection therewith. Except where otherwise indicated in the Presentation, the information provided therein is based on matters as they exist at the date of preparation of the Presentation and not as of any future date and will be subject to updating, revision, verification and amendment without notice and such information may change materially. Neither the Company nor its subsidiary undertakings, or any of such persons' Associates is under an obligation to update, revise or keep current the information contained in this Presentation to which it relates or to provide the recipient of this Presentation with access to any additional information that may arise in connection with it and any opinions expressed in this Presentation are subject to change without notice. Nothing contained in this Presentation is or should be relied upon as a promise or representation as to the future.

To the extent available, the industry and market data contained in this Presentation has come from official or third party sources. Third party industry publications, studies and surveys generally state that the data contained therein have been obtained from sources believed to be reliable, but that there is no guarantee of the accuracy or completeness of such data. While the Company believes that each of these publications, studies and surveys has been prepared by a reputable source, the Company has not independently verified the data contained therein. In addition, certain of the industry and market data contained in this Presentation come from the Company's own internal research and estimates based on the knowledge and experience of the Company's management in the market in which the Company operates. While the Company believes that such research and estimates are reasonable and reliable, they, and their underlying methodology and assumptions, have not been verified by any independent source for accuracy or completeness and are subject to change without notice. Accordingly, undue reliance should not be placed on any of the industry or market data contained in this Presentation.

This Presentation, information and opinions contained in this Presentation and the materials distributed in connection with this Presentation are not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction.

The information, statements and opinions contained in this Presentation do not constitute a public offer under any applicable legislation or an offer to sell, or a solicitation of an offer to purchase, any securities in and are not for release, publication or distribution (directly or indirectly) in or into the United States, its territories or possessions, Canada, Japan, Australia or the Republic of South Africa or any other jurisdiction where such distribution or offer is unlawful, except in the United States to a limited number of qualified institutional buyers as defined in Rule 144A under the US Securities Act of 1933, as amended (the "Securities Act"). Any securities referred to in this Presentation have not been, and will not be, registered under the Securities Act or under the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in or into the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act.

This Presentation includes statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "targets", "forecasts", "expects", "intends", "plans", "may", "will" or "should" or, in each case, their negative or other variations or comparable terminology; by the forward-looking nature of discussions of strategy, plans or intentions; or by their context. These forward-looking statements include all matters that are not historical facts. They appear in a number of places and include, but are not limited to, statements regarding the Group's intentions, beliefs or current expectations concerning, amongst other things, results of operations, financial condition, liquidity, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they are based on numerous assumptions regarding the Company's present and future business strategies and future events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance and the actual results of operations, financial condition, liquidity, prospects, growth and the development of the industry in which the Group operates, may differ materially from those made in or suggested by the forward-looking statements set out in this Presentation. Past performance of the Company cannot be relied on as a guide to future performance. Forward-looking statements speak only as at the date of this Presentation and the Company and any of its subsidiary undertakings or any of such persons' respective directors, officers, employees, agents, affiliates or advisers expressly disclaims responsibility for the accuracy of the opinions expressed in this Presentation or the underlying assumptions, and any obligations or undertaking to release any update of, or additions or revisions to, any forward-looking statements in this Presentation. As a result, you are cautioned not to place any undue reliance on such forward-looking statements. In addition, even if the results of operations, financial condition and liquidity of the Group, and the development of the industry in which the Group operates, are consistent with the forward-looking statements set out in this Presentation, those results or developments may not be indicative of results or developments in subsequent periods.

All intellectual property in, related to or disclosed by this document or any information, software, hardware, product or service described herein ("Information") is the property of Sanius Health or its licensors; no right in or title to the same is granted to any person by provision of this Information which is provided 'as is' for information purposes only.

To the extent allowed by law, Sanius Health gives no warranty or representation regarding the Information, and disclaims all express and implied warranties regarding the same including without limitation regarding accuracy, performance or fitness for purpose. Sanius Health assumes no duty to any person by providing the Information and to the extent allowed by law excludes all liability relating to such provision or reliance by any person, including without limitation any direct loss or indirect or consequential loss even if advised of the possibility of the same. All Information is confidential, intended for the authorised addressees only and not for further distribution.

Welcome

The KOL Haematology Research, Strategy and Support Forum

It is with great pleasure that we invite you to join us for the [KOL Haematology Research, Strategy and Support Forum](#), which will take place at Central Hall Westminster, on [9th May 2025](#).

Organised by Sanius Health, the day focuses on bringing together key clinical leaders, pharmacists, nurses and leaders within the haematology sphere. Our forum brings together key KOLs within every haematology disease area, for sessions focused on [knowledge sharing](#), research insights, and supporting our colleagues with support around [burnout, wellness and resilience](#) to manage the workload pressures.

The KOL Haematology Research, Strategy and Support Forum takes place in close proximity to [the Haematology Patient and Carer Congress \(HPCC25\)](#), creating a unique synergy in the field of haematology. The HPCC25 will draw thousands of haematology patients from across Europe, while the Research and Strategy Forum will host an impressive array of clinical leaders in the field.

Colleagues will have the opportunity to [join both the HPCC25 in the morning, and the KOL Research and Strategy Forum in the afternoon](#), or can of course choose to attend [purely one event on the day](#).

The KOL Research, Strategy and Support Forum

Agenda and Programme

Forum Programme

About the Programme

The programme will include outstanding plenary speakers, a wide range of parallel sessions, abstract presentations and industry educational symposia.

Networking Pods

Spaces to connect with clinical and research colleagues.

Interactive Exhibitions

Demonstrating lived and applied innovations towards patient care.

Engagement Workshops and Symposia

Exploring key challenges, priorities and insights from lead clinicians.

Thought Leadership Round Tables

Thought leadership driven conversations by key opinion leaders on challenges and advancements.



Our Key-Note Speakers and Panellists



Dr Shirley D'Sa, MD, FRCP, FRCPath
 Consultant Haematologist & Clinical Lead | Honorary Associate Professor at the UCL Cancer Institute. UCLH NHS Foundation Trust



Professor Claire Harrison
 Professor of myeloproliferative neoplasms and Deputy CMO at Guy's and St Thomas' Hospital NHS Foundation Trust



Dr. Sue Pavord
 President of British Society for Haematology, Consultant Haematologist at Oxford University Hospitals NHS FT, Director of Oxford Iron Clinic



Eric Low
 Former CEO of Myeloma UK



Professor Karthik Ramasamy
 Consultant Haematologist, Oxford University Hospitals NHS



Dr Sanne Lughart
 Consultant Haematologist, University Hospitals Bristol NHS



Professor Charles Craddock
 Director of Blood and Marrow Transplant Unit, Queen Elizabeth Hospital Birmingham



Chantelle Hughes
 Senior Research Nurse, University College London Hospitals NHS



Professor Ashutosh Wechalekar
 Consultant Haematologist, Royal Free London NHS



Professor Guy Pratt
 Honorary Consultant Haematologist, University Hospitals Birmingham NHS



Sir Peter Homa
 Former Director General, Defence Medical Services and Former Chief Executive for the Healthcare Commission, Former Chair for Health Education England



Dr Emma Searle
 Consultant Haematologist, The Christie Hospital

May 09 2025

Full Day's Agenda and Flow

- ▶ Keynote and Panel Discussions
- ▶ Patient and Plenary Sessions
- 👤 Networking Session
- 🌐 Partner Sponsored Session
- 📖 Education Series
- 📡 Expert Session

Location: QE11, Fleming Room

Location: Britten

Location: Britten

08:30 **Haematology Patient and Carer Congress Begins**

08:30 **Breakfast and Registration**

Wellness Hall Opens: Smoothies, Massages, Fireside Chats and Patient Org Stands 👤

👤 Speed Chatting with Patients and Networking
Room: Britten

09:30 **Keynote Presentations**

👤 Speed Chatting with Patients and Networking
Room: Britten

09:30 Welcome to HPCC - Orlando Agrippa, CEO, Sanius Health ▶

09:45 Dr Sue Pavord, President, British Society of Haematology ▶

10:05 Patient Experience Speaker ▶

10:30 Blood Cancer UK | Awareness Presentation ▶

10:50 Exploring Patient Access: The Role of Innovation and Technology in Patient Empowerment - Panel Discussion ▶

11:45 **KOL Research, Strategy and Support Forum Begins**
Central Hall Westminster

👤 Fireside Chats with Lunch
Room: Britten

Clinical colleagues to move from QE11 Centre to the building next door for the KOL Strategy Forum
Central Hall Westminster, Library Room

👤 Fireside Chats with Lunch
Room: Britten

12:00 **3 Course Lunch and Networking Session with Clinical Colleagues** 👤

May 09 2025

Continued: Agenda and Flow

-  Keynote and Panel Discussions
-  Networking Session
-  Partner Sponsored Session
-  Education Series
-  Patient and Plenary Sessions
-  Expert Session

Location: Central Hall Westminster - Library and Lecture Hall

Location: Central Hall Westminster Private Meeting Room

11:45 KOL Research, Strategy and Support Forum Begins
Central Hall Westminster

Clinical colleagues to move from QE11 Centre to the building next door for the KOL Strategy Forum
Central Hall Westminster, Library Room

12:00 3 Course Lunch and Networking Session with Clinical Colleagues

13:00 Clinical Haematology Innovation Symposium Opens

13:15 Karthik Ramasamy, Consultant Haematologist, Oxford University Hospitals NHS
Castlemans Awareness Discussion

14:00 Professor Claire Harrison, Deputy CMO at GSTT NHS Foundation Trust

14:45 Clinical Leadership Training, Handling Burnout, Fatigue and Finding Support
Peter Homa CBE, Former Chair of Health Education

15:30 Prof Charles Craddock, Professor of Haemato-oncology, University of Birmingham
Transforming UK Trial Delivery

16:00 What's Next in Haematology: How Are Innovations Shaping the Future?
Featuring: Professor Guy Pratt, Professor Shirley D'Sa, Professor Ashu Wechelekar, Dr Sanne Lugthart, Dr Emma Searle. Chaired by Orlando Agrippa.

16:30 Professor Shirley D'Sa, University College London Hospitals
CAD Awareness Discussion

16:45 Afternoon Tea and Networking

14:00 Nurse and Pharmacist Bispecific Training Session
Led by: Chantelle Hughes, Senior Research Nurse, University College London Hospitals NHS Foundation Trust
Private Room



15:30 Clinical Leadership Training Sessions
Led by: NHS Clinical Leaders Network
Private Room

Venue

Central Hall Westminster |
 Storey's Gate, London SW1H 9NH

We are delighted to host the forum in London, with fantastic train and road access to all international airports.

Central Hall Westminster stands as a premier conference and events destination in the heart of London. This Grade II* listed edifice, boasting breathtaking views of Westminster Abbey, offers an array of 23 adaptable spaces spread across four floors. Renowned for its versatility, the venue accommodates a wide spectrum of events, with a particular focus on high-profile and tailor-made events.



The option to attend multiple events in one day, one location.

The Haematology Patient & Carer Congress

9th May 2025, QE11 Centre Westminster.

Europe's Largest Patient, NHS and Carers event is here

Building on the resounding success of our 2024 event, the Patient and Carers Congress 2025 is poised to be Europe's premier and most impactful gathering yet. We're raising the bar even higher – delivering world-class speakers, fully immersive experiences, and unmatched networking opportunities that will truly accelerate patient outcomes, therapies access and innovation for the community.

Bringing together communities across different types of cancer, Waldenström's Macroglobulinemia and Myeloproliferative Neoplasms to Sickle Cell Disease, Myeloma, Chronic Myeloid Leukaemia, Chronic Lymphocytic Leukaemia, Acute Myeloid Leukaemia and more, the HPCC25 is set to create an energising atmosphere of learning and advancement. Shared experiences, expertise, and insights will catalyse innovations that increase the potential for developing safer, more effective medicines and care approaches.

Bigger in scale, bolder in vision, and elevated in impact - the HPCC25 promises to be an unmatched experience you won't want to miss.

HPCC in Numbers




Two thousand plus **Patients.**



Two hundred **Clinicians.**



One hundred **NHS Executives.**



Ten **Industry Partners.**




Ten **Thought Leadership Speakers.**



Twenty **Patient Organisations.**



HPCC 2024 Founding Partners



KOL2025
KOL2025
KOL2025
KOL2025

**The KOL Haematology Research, Strategy and Support Forum |
Thank You.**